During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

An expert discusses that while CAR T-cell therapy has transformed the treatment landscape for primary refractory diffuse ...

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the urgent need for a shift in therapeutic strategy following early relapse ...

In an interview with Targeted Oncology, Benjamin Schlechter, MD, Senior Physician in the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, discusses the unmet needs for patients with ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...